ANEB News and Press, Anebulo Pharmaceuticals Inc. From 09/12/23

2023-09-12 12:52:44 ET Gainers: Anebulo Pharmaceuticals ( ANEB ) +35% . WeWork ( WE ) +34% . Shengfeng Development Limited ( SFWL ) +29% . AEON Biopharma ( AEON ) +28% . Avalo Therapeutics ( AVTX ) +28% . The Beauty Health Co...

Anebulo Pharmaceuticals Inc. (ANEB) is expected to report for Q4 2023 Minera IRL Ltd ADR (MRLLY) is expected to report for Q3 2023 OpenLocker Holdings Inc (OLKR) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-0.43 for Q2 2024 Sompo Holdings I...

Anebulo Pharmaceuticals Inc. (ANEB) is expected to report for Q4 2023

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced that it will be giving...

FDA provides favorable input on studies to support ANEB-001 approval Part C Extension of Phase 2 trial completed exploring THC challenge dose of up to 60 mg Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (the “Company” or “Anebulo”), a clinical-stag...

NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subje...

2023-05-11 12:17:22 ET Anebulo Pharmaceuticals press release ( NASDAQ: ANEB ): Q1 GAAP EPS of -$0.11. Cash was $14.2 million as of March 31, 2023. For further details see: Anebulo Pharmaceuticals GAAP EPS of -$0.11

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates PR Newswire AUSTIN, Texas , May 11, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel s...

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication PR Newswire ANEB-001 statistically significantly reduced VAS Feeling High in all cohorts (p=<0.0001 at the 30 mg...

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions PR Newswire Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill Advisors Sandra Gardiner succeeds Rex Merchant as acting chief financial officer ...